|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 December 2000, Vol. 96, No. 13, pp. 4307-4312
NEOPLASIA
Differential effects of CD30 activation in anaplastic large cell
lymphoma and Hodgkin disease cells
Samy S. Mir,
Bettina W. M. Richter, and
Colin S. Duckett
From the Metabolism Branch, Division of Clinical
Sciences, National Cancer Institute, National Institutes of Health,
Bethesda, MD.
CD30 is a member of the tumor necrosis factor (TNF) receptor
superfamily that is expressed on activated lymphocytes, as well as on
neoplastic cells of Hodgkin disease (HD) and anaplastic large cell
lymphoma (ALCL). A number of reports have shown that, depending on
cellular context, CD30 signaling can exert a variety of effects,
ranging from cell death to cellular proliferation. In the present study
this disparity was examined, using a number of ALCL- and HD-derived
cell lines. Activation of CD30 led to the induction of apoptotic death
of ALCL cells, along with the selective reduction of TNF
receptor-associated factor 2 and impairment in the ability of these
cells to activate the pro-survival transcription factor nuclear factor
 B (NF-B). In contrast, HD cells, which constitutively express
NF-B, were not susceptible to CD30-induced apoptosis but could
be sensitized following ectopic overexpression of a superdominant
IB. These studies suggest that NF-B plays a determining role in
the sensitivity or resistance of lymphoma cells to CD30-induced
apoptosis, which may have important consequences in the clinical
treatment of CD30-positive neoplasia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest?
- Edi Levi, Walther M. Pfeifer, Marshall E. Kadin, Samy S. Mir, Bettina W. M. Richter, and Colin S. Duckett
Blood 2001 98: 1630-1632.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. Menzel, T. Schirrmann, Z. Konthur, T. Jostock, and S. Dubel
Human antibody RNase fusion protein targeting CD30+ lymphomas
Blood,
April 1, 2008;
111(7):
3830 - 3837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Hirsch, M. Hummel, S. Bentink, F. Fouladi, R. Spang, R. Zollinger, H. Stein, and H. Durkop
CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells
Am. J. Pathol.,
February 1, 2008;
172(2):
510 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2259 - 2267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al.
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
PNAS,
May 15, 2007;
104(20):
8444 - 8448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Wright, J. M. Rumble, and C. S. Duckett
CD30 Activates Both the Canonical and Alternative NF-{kappa}B Pathways in Anaplastic Large Cell Lymphoma Cells
J. Biol. Chem.,
April 6, 2007;
282(14):
10252 - 10262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Krysov, T. F. Rowley, and A. Al-Shamkhani
Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells
Mol. Cancer Ther.,
February 1, 2007;
6(2):
703 - 711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, J. Janik, M. W. Brechbiel, and T. A. Waldmann
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Blood,
July 15, 2006;
108(2):
705 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Boll, H. Hansen, F. Heuck, K. Reiners, P. Borchmann, A. Rothe, A. Engert, and E. Pogge von Strandmann
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis
Blood,
September 1, 2005;
106(5):
1839 - 1842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Janik, J. C. Morris, S. Pittaluga, K. McDonald, M. Raffeld, E. S. Jaffe, N. Grant, M. Gutierrez, T. A. Waldmann, and W. H. Wilson
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma
Blood,
November 15, 2004;
104(10):
3355 - 3357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Minekawa, T. Takeda, M. Sakata, M. Hayashi, A. Isobe, T. Yamamoto, K. Tasaka, and Y. Murata
Human breast milk suppresses the transcriptional regulation of IL-1{beta}-induced NF-{kappa}B signaling in human intestinal cells
Am J Physiol Cell Physiol,
November 1, 2004;
287(5):
C1404 - C1411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Berro, G. A. Perry, and D. K. Agrawal
Increased Expression and Activation of CD30 Induce Apoptosis in Human Blood Eosinophils
J. Immunol.,
August 1, 2004;
173(3):
2174 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Olszewski and M. L. Grossbard
Empowering Targeted Therapy: Lessons from Rituximab
Sci. Signal.,
July 13, 2004;
2004(241):
pe30 - pe30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
CD56+ Lymphoma With Skin Involvement: Clinicopathologic Features and Classification
Arch Dermatol,
April 1, 2004;
140(4):
427 - 436.
|
|
|
|
|
|
|
T. Nijsten, C. Curiel-Lewandrowski, and M. E. Kadin
Lymphomatoid Papulosis in Children: A Retrospective Cohort Study of 35 Cases
Arch Dermatol,
March 1, 2004;
140(3):
306 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Matsumoto, M. Terakawa, K. Miura, S. Fukuda, T. Nakajima, and H. Saito
Extremely Rapid and Intense Induction of Apoptosis in Human Eosinophils by Anti-CD30 Antibody Treatment In Vitro
J. Immunol.,
February 15, 2004;
172(4):
2186 - 2193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Borchmann, J. F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.-f. Zhang, T. Davis, T. Keler, V. Diehl, et al.
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
Blood,
November 15, 2003;
102(10):
3737 - 3742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Z. Rassidakis, M. P. Oyarzo, and L. J. Medeiros
BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Blood,
August 1, 2003;
102(3):
1146 - 1147.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Willers, R. Dummer, W. Kempf, T. Kundig, G. Burg, and M. E. Kadin
Proliferation of CD30+ T-Helper 2 Lymphoma Cells Can Be Inhibited by CD30 Receptor Cross-Linking with Recombinant CD30 Ligand
Clin. Cancer Res.,
July 1, 2003;
9(7):
2744 - 2754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nishikori, Y. Maesako, C. Ueda, M. Kurata, T. Uchiyama, and H. Ohno
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease
Blood,
April 1, 2003;
101(7):
2789 - 2796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Harlin, E. Podack, M. Boothby, and M.-L. Alegre
TCR-Independent CD30 Signaling Selectively Induces IL-13 Production Via a TNF Receptor-Associated Factor/p38 Mitogen-Activated Protein Kinase-Dependent Mechanism
J. Immunol.,
September 1, 2002;
169(5):
2451 - 2459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Wahl, K. Klussman, J. D. Thompson, J. H. Chen, L. V. Francisco, G. Risdon, D. F. Chace, C. B. Siegall, and J. A. Francisco
The Anti-CD30 Monoclonal Antibody SGN-30 Promotes Growth Arrest and DNA Fragmentation in Vitro and Affects Antitumor Activity in Models of Hodgkin's Disease
Cancer Res.,
July 1, 2002;
62(13):
3736 - 3742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagata, M. Onda, Y. Numata, K. Santora, R. Beers, R. J. Kreitman, and I. Pastan
Novel Anti-CD30 Recombinant Immunotoxins Containing Disulfide-stabilized Fv Fragments
Clin. Cancer Res.,
July 1, 2002;
8(7):
2345 - 2355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fotin-Mleczek, F. Henkler, D. Samel, M. Reichwein, A. Hausser, I. Parmryd, P. Scheurich, J. A. Schmid, and H. Wajant
Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8
J. Cell Sci.,
January 7, 2002;
115(13):
2757 - 2770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Vinante, A. Rigo, M. T. Scupoli, and G. Pizzolo
CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540
Blood,
January 1, 2002;
99(1):
52 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Levi, W. M. Pfeifer, M. E. Kadin, S. S. Mir, B. W. M. Richter, and C. S. Duckett
CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest?
Blood,
September 1, 2001;
98(5):
1630 - 1632.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Mariner, V. Lantz, T. A. Waldmann, and N. Azimi
Human T Cell Lymphotropic Virus Type I Tax Activates IL-15R{{alpha}} Gene Expression Through an NF-{{kappa}}B Site
J. Immunol.,
February 15, 2001;
166(4):
2602 - 2609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
